Biosfer Teslab, a spin-off company of the Rovira i Virgili University (URV) and the Pere Virgili Health Research Institute (IISPV) operates in the field of in vitro diagnostics to provide analytical services to study and monitor alterations in lipid metabolism and its associated cardiovascular risk.
Biosfer appeared with the aim of reducing the time between the basic scientific results and their future application in patients and of becoming a reference company at European level in the analysis of biofluids using the Nuclear Magnetic Resonance (NMR) high-performance technology.
As a result of this vocation, the “Liposcale” test was born, which revolutionizes the characterization of the lipoprotein profile (particles that transport lipids through the blood stream), allowing a direct and rapid determination of the size and number of particles of the main classes of Lipoproteins (VLDL, LDL and HDL), as well as the concentration of particles of nine different subclasses, without having to fractionate the plasma.
Since August 2014, Laboratorios Rubio, a family-owned pharmaceutical company specialized in therapeutic solutions for low’prevalence diseases, has been part of Biosfer Teslab’s social capital, enabling the industrial development of the Liposcale® test with the aim of launching the test at a European level. In addition, Rubió Laboratories are the national and European marketers of the Liposcale® test.
Likewise, at Biosfer Teslab we are committed to constant technological innovation to always provide the best service to our customers. Our extensive experience in NMR has allowed us to expand our service portfolio and also offer the characterization of low molecular weight metabolites in intact serum, the glycoprotein test in intact serum, lipidomics in serum and characterization of aqueous metabolites for cell cultures, cell media and tissues (both animal and human).
Provide services of analysis of fluids and biological tissues by NMR and develop medical software, to help and facilitate to the health professionals and the scientific community to study, diagnose and treat metabolic disorders in order to advance in knowledge and improve the health of people.
To be a benchmark biotechnology company, well connected to the key actors that are involved in the international biomedical research network, and committed to innovation and continuous improvement.
We are scientists experts in nuclear magnetic resonance and bioinformatics. We understand that each experiment is unique and therefore we attend to our clients in a personalized way, both the questions and doubts that may arise from the beginning of the experiment to the publication of the results. We have great experience collaborating with different research groups in a wide range of pathologies as our publications show.
Nuclear magnetic resonance is a high throughput technique. We work constantly to reduce analysis time in order to offer competitive prices. In this way, the client benefits from our innovation and we can offer an affordable tool for research projects.
In addition, we offer customization of statistical analysis, which can include from descriptive analysis, univariate analysis, multivariate analysis, to correlation analysis, predictive models, pattern recognition or epidemiological studies. In order to help the client in the interpretation of the results, we can also perform custom graphic design, differentiating us from a classic analysis service.
Metabolomics Platform: It is an investigation infrastructure led by the Prof. Xavier Correig which is property from the CIBER de Diabetes y Enfermedades Metabólicas (CIBERdem) and the URV. Metabolomics Platform is focused on developing metabolic techniques and using them at the biomedicine and biotechnology fields, from the scientific collaboration with other investigation groups.
Universitat Rovira i Virgili: The URV promotes the creation of new companies with the aim of supporting the entrepreneurship and the investigation in different fields. Apart from Biosfer Teslab, the university has others spin off companies, founded from the work of professors and young investigators.
Institut d’Investigació Sanitària Pere Virgili: It was created in the frame of a scientific collaboration between l’Institut Català de la Salut, the GRUP SAGESSA, the Grup Pere Mata and the URV. The IISPV, which concentrates the biomedical and clinical investigation groups and the hospitals from the south of Catalonia, has as main objective being a national and international reference centre in biomedical investigation.
Laboratorios Rubió: Laboratorios Rubió is since 2014 one of the partners of Biosfer Teslab. This familiar company was founded in 1968 and is characterized by being a pioneer in the pharmaceutical field. Rubió promotes its products nationally and internationally, being present in Europe, America, Africa, Asia and Middle East.
Centre Tecnològic de Nutrició i Salut: is a centre created in 2008 by Acció, the URV and 16 others institutions and companies to support the Catalan R+D+i in nutrition and health. This centre manages the part of the Servei de recursos Científics i Tècnics (SRCiT) from the URV where there are the Nuclear Magnetic Resonance (NMR) facilities.
Centre for Omic Sciences: The COS is a scientific operator created by the URV and located at the CTNS. It collaborates with Biosfer Teslab through the NMR service that offers to companies and academic research groups.
Hospital Universitario Sant Joan de Reus: hospital that collaborates with Biosfer Teslab usign the Liposcale test.
Grants and Financial Resource
These are the financial resource that Biosfer Teslab have obtained.
Industrial doctoral Plan Fellowship
BIOSFER TESLAB, SL supported by CDTI under the NEOTEC Operational Programme is implementing the Development of new in vitro test based on Nuclear Magnetic Resonance (NMR) spectroscopy for an early detection of cardiometabolic diseases and cardiovascular diseases.
BIOSFER TESLAB, SL with the support of ACTION in the frame of the Operative Program FEDER Catalonia 2014-2020 has carried out the “DEVELOPMENT And VALIDATION OF ADVANCED DIAGNOSTIC TEST Of INFLAMMATION And INSULIN RESISTANCE FOR THE IMPROVEMENT OF CARDIOVASCULAR RISK USING NUCLEAR MAGNETIC RESONANCE” (RD15-1-0013).
Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.
In particular, the company has developed a glycoprotein test and a LMWM test – that includes, branched amino acids -, as they have been identified as inflammatory markers and involved in insulin resistance processes, respectively.
The Agency for the Competitiveness of the Company, ACTION, aiding to industrial research centers and experimental development, has granted Biosfer Teslab with an amount of 67,728.97 €.
This aid is programmed in the axis 1, “Boost research, technological development and innovation”, specific objective OE 1.2.2, “Transfer and spreading of technology and cooperation between companies and universities or other research centers”, line of action “Collaborative R+D projects” under the framework of the FEDER Operational Program of Catalonia 2014-2020
ENISA: It is a public company – dependent of the Ministry of Industry, Energy and Tourism, via the General Directorate of Industries and small and medium-sized enterprises – that, since 1982, is also actively involved in the financing of innovative and viable business projects.
These are the awards that Biosfer Teslab has won. All of them have the main goal of promote new companies and jobs in the territory.
Innovate SME: Ministry of the Economy, Industry and Competitiveness awards the company Biosfer Teslab as a certified innovate sme.
ISO 9001:2015 : Biosfer Teslab have the ISO 9001 Certification approved by TÜVRheinland.
ISO 13485:2016: Biosfer Teslab have the ISO 13485 Certification approved by SGS